Hey Webmasters! New Photo Album Service Launched - Check it out!
|
|
|
About the NCRI
The National Cancer Research Institute (NCRI) was established in April 2001. It is a partnership between government, the voluntary sector and the private sector, with the primary mission of maximising patient benefit that accrues from cancer research in the
The NCRI consists of: The Association of British Pharmaceutical Industry (ABPI); The Association for International Cancer Research; The Biotechnology and Biological Sciences Research Council; Breakthrough Breast Cancer; Breast Cancer Campaign;Cancer Research UK; Department of Health; Economic and Social Research Council; Leukaemia Research Fund; Ludwig Institute for Cancer Research; Macmillan Cancer Support; Marie Curie Cancer Care; The Medical Research Council; Northern Ireland Health and Personal Social Services Research & Development Office; Roy Castle Lung Cancer Foundation; Scottish Executive Health Department; Tenovus; Wales Office of Research and Development for Health & Social Care; Wellcome Trust; and Yorkshire Cancer Research. AstraZeneca is the gold sponsor for the NCRI Cancer Conference 2006.
STRAIGHT FROM THE DOCTOR
Los Angles, CA - February 16, 2005 - The Electronic Retailing Self-Regulation Program ("ERSP"), the electronic direct-response industry's self-regulatory program supervised by the National Advertising Review Council ("NARC"), announced that clinical skincare manufacturer Murad, Inc. provided a reasonable basis for its claim that the Murad Acne Complex® has a "90% success rate" at effectively treating acne conditions. The NARC also found that Murad’s tag line “Get Clear. Stay Clear™” for acne was reasonable in light of its effectiveness at treating acne and the visible factors of breakouts. Murad’s acne claims were successfully defended from attack by an unnamed competitor, which tried but failed to stop Murad from making its acne success rate claim. During the substantiation process, Murad provided ample support for the acne claim and established that it did indeed have a reasonable basis to claim such a success rate with its Acne Complex® kit.
"With millions of people affected by acne, it was my goal to create an easy, three-step system that would care for the varying skin types, clearing the acne without drying the skin," says Dr. Howard Murad, dermatologist, pharmacist, Associate Clinical Professor of Dermatology at UCLA, founder of Murad, and author of Wrinkle-Free Forever and the Cellulite Solution. With its innovative solutions for treating acne, Murad has sold over one million Acne Complex® Kits. The Acne Complex® Kit is a simple approach to attacking a complicated concern.
"Murad invests substantial resources in research, development and testing. We see the incredible success our products have on the consumer everyday from Dr. Murad’s patients, clients of the Murad Medical Spa and the many customers who write and tell us how much Murad has helped them. We never doubted that our acne claim could be supported" said Richard Murad, the company's Chief Operating Officer and General Counsel. “While we disagreed with the conclusions of the ERSP on certain non-acne related issues, we will take the recommendations of the ERSP into consideration in developing future advertising for Acne Complex. Overall we would encourage other companies to voluntarily submit to the process. It not only protect the interests of consumers, but also improves the industry standards for everyone."
Founded in 1989, Murad is the leading manufacturer of clinically based, doctor developed and scientifically proven skincare products. In addition to its topically applied selection of products targeted to address concerns from acne to aging, Murad is widely acknowledged as the founder and pioneer of Internal Skincare® the science of using nutritional supplements to improve the health of the skin. All Murad products incorporate the "Water Principle," an anti-aging theory discovered by Dr. Murad that promotes optimal skin health through the prevention of cellular water loss. Murad products are sold throughout the world at specialty retail locations and salons and spas. Murad products are also sold on its website http://www.murad.com/.
Women with a faulty version of a gene called BRIP1 have an increased risk of developing breast cancer, according to the results of a Cancer Research UK funded study revealed at the National Cancer Research Institute (NCRI) Cancer Conference and published in today’s Nature Genetics*.
Scientists from The Institute of Cancer Research studied (cancer research uk) the BRIP1 gene in 1212 women with breast cancer who had a family history of the disease that was not due to the known breast cancer genes, BRCA1 or BRCA2. They compared these women to 2081 healthy people. They found nine BRIP1 faults (mutations) in the breast cancer patients but only two in the healthy individuals. This indicates that the gene is linked to breast cancer more often than would be expected by chance.
The team worked out that carrying a faulty version of BRIP1 doubled a women’s risk of the disease – taking their risk by the age of 70 from one in twelve to around one in six. This discovery could help identify women at increased risk of developing breast cancer, allowing preventative measures to be undertaken and leading to better diagnosis and more tailored treatment in the future.
The
The Institute and The Royal Marsden NHS Foundation Trust work in a unique partnership, forming the largest comprehensive cancer centre in
The
The Institute is a charity that relies on voluntary income. The Institute is one of the world’s most cost-effective major cancer research organisations with over 90p in every £ directly supporting research.
Cancer Research
bravenet.com